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 Introduction 
 Disseminated superficial actinic porokeratosis (DSAP) 
is the most common porokeratosis, first presenting in the 
4th decade of life or later, and manifesting with wide-
spread multiple small annular lesions on sun-exposed ar-
eas  [1] . Histological presentation with a column of para-
keratotic keratinocytes in a small epidermal invagination, 
also known as  cornoid lamella , is considered a classical 
hallmark of all subtypes of porokeratosis. DSAP lesions 
are reported to have the potential of transformation into 
squamous cell carcinoma, Bowen’s disease, or basal cell 
carcinoma  [2] and usually cause cosmetic disturbances, 
therefore treatment is indicated. Various pharmacologi-
cal and physical treatment options exist, but to our knowl-
edge there is only 1 case report of successful porokeratosis 
treatment with grenz rays  [3] . We present 8 cases of 
DSAP, successfully treated with radiotherapy (RTx) at the 
University Hospital Zurich.
 Patients and Methods 
 For further details, see the supplementary material (for all on-
line suppl. material, see www.karger.com/10.1159/000478855) 
( Fig. 1 ).
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 Abstract 
 Background: Disseminated superficial actinic porokeratosis 
(DSAP) is a rare keratinization disorder with potential malig-
nant transformation, for which present treatment strategies 
show limited success.  Aim: To evaluate the response of DSAP 
lesions to grenz ray radiotherapy (RTx).  Methods: Data of pa-
tients treated with RTx at University Hospital Zurich, Switzer-
land, between 2004 and 2015, were reviewed. Patients with 
DSAP, who received at least 1 RTx treatment session and 
who had been followed up for at least 4 weeks were included 
in the further data analysis.  Results: The study cohort con-
sisted of 8 patients with a median age of 73 years (range 
54–84). All were treated with grenz rays for DSAP. Most (7/8) 
patients showed complete clinical clearing of the lesions. All 
patients experienced temporary side effects of RTx, which 
resolved within 4 weeks after the last irradiation.  Conclu-
sion: We suggest radiotherapy with grenz rays as a treat-
ment option for DSAP.  © 2017 S. Karger AG, Basel 
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 Results 
 The patient population included 5 men and 3 women, 
aged between 54 and 84 years (median 73). The patients 
had had the condition for at least 6 years prior to the first 
consultation at our clinic, and 7 out of 8 were pretreated 
with cryotherapy (5/7), photodynamic therapy (PDT) 
(5/7), topical steroids or other agents, such as imiquimod 
or ingenol mebutate. The used therapies showed only 
limited success, and all patients needed additional treat-
ment. 
 Seven out of 8 patients had a history of actinic kerato-
sis, while 6 out of 8 had been diagnosed with nonmela-
noma skin cancer. The only patient who did not have a 
history of malignant skin lesions was also the youngest 
(54 years old). The distribution pattern of DSAP and cu-
taneous malignancies in the treatment population is 
shown in  Figure 2 . 
 All patients were treated with grenz rays (10 kV); 2 pa-
tients were additionally treated with soft rays (20 kV, 10–
12 × 4 Gy) for Bowens’ carcinoma and superficial squa-
mous cell carcinoma. The total dose per field ranged from 
28 to 52 Gy and was given at 3- to 4-day intervals for 6–10 
sessions. In 1 case the therapy had to be discontinued af-
ter 6 sessions because of grade 5 acute reaction to RTx 
 Table 1.  Clinical details of patients with DSAP
Pat. Age, 
years/sex
Localization Other skin pre-/
malignancies
Previous therapy Total dose, 
Gy/RT type
Irradiated area, 
m2/fields, n
Radio-
dermatitis
FU, months/
relapse
1 81/F Lower legs,
forearms
AK, BCCs Cryo, PDT 48/GR 0.0079/1 E3 26/no
2 73/M Legs, arms, 
back
AKs, BCCs, 
SCC
Mometasone cream 1 mg/g, Cryo, PDT, 
imiquimod cream 5%
36/GR 0.094/4 E3 3/no
3 74/F Legs and 
forearms
AKs, BCC Cryo, ingenol mebutate 150 μg/g 29/GR 1.964/28 E3 46/clinically 
suspected
4 84/M Lower legs, 
forearms
MB – 32/GR 0.1931/5 E4 2/no
5 71/M Lower legs, 
forearms
BCC, SCC, 
melanoma
Cryo, PDT, diclofenac gel 3% 52/GR 0.1713/4 E2 2/no
6 73/F Forearms Bowen’s Ca, 
SCC
Tretinoin cream 0.05% 44/GR-SR 0.0824/7 E2 4.5/no
7 77/M Legs MB, AK Adapalene cream, imiquimod cream 5%, 
Cryo
48/GR at least 
1.4995/25
E3 65/no
8 54/M Lower legs – Acitretin 25 mg caps, PDT 30/SR-GR was not 
measured/10
E5 24/no
 Radiodermatitis: highest grade during treatment; FU, follow-up since the end of the first radiotherapy session; AK, actinic keratosis; BCC, basal cell car-
cinoma; Bowen’s Ca, Bowen’s carcinoma; Cryo, cryotherapy; GR, grenz rays; MB, Morbus Bowen; SCC, squamous cell carcinoma; SR, soft rays.
Assessed for eligibility
Patients with
• Clinically or histologically diagnosed DSAP
• Treated with radiotherapy
• Follow-up no less than 4 weeks
• Informed consent
n = 2,000
n = 8
• Clinically parameter of DSAP
• Concomitant cutaneous pre- and malignancies
• Adverse events
• Patient demographics
University Hospital Zurich, Switzerland
 Fig. 1. Flowchart of Materials and Methods. 
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(patient 5). All patients were seen at least 4 weeks after 
RTx had ended and then were followed up for a median 
of 21.41 months (range 2–65 months). 
 At the time of the last follow-up, only 1 patient (patient 
3) was clinically suspected to have 1 relapse lesion in the 
area, irradiated 4 years ago, but refused further investiga-
tion or treatment. No patients developed nonmelanoma 
skin cancer in the irradiated fields; however, 6 patients 
developed actinic keratosis or nonmelanoma skin cancer 
in other areas. 
 The patient characteristics are listed in  Table 1 ; patient 
examples are provided in  Figures 3 and  4 .
 Discussion 
 DSAP, although described more than 100 years ago, 
still lacks consistency in etiology and pathogenesis. Ultra-
violet light, genetic factors (autosomal dominant inheri-
tance, mutations in mevalonate kinase pathway)  [4] , im-
munosuppression, drugs, infections, and trauma  [1] have 
all been reported to favor the development of DSAP. Ir-
radiation with X-rays has been reported to provoke poro-
keratosis in 2 cases  [5, 6] . Most hypotheses regarding the 
etiology state faulty maturation and early apoptosis rath-
er than an increased rate of proliferation of keratinocytes 
being responsible for the formation of a cornoid lamella 
 [4, 7] . Given the fact that all patients from our cohort de-
Basal cell carcinoma
– Head and neck = 11
– Arms = 1
– Legs = 0
– Trunk = 5
Actinic keratosis
– Head and neck = 13
– Arms = 18
– Legs = 3
– Trunk = 4
Morbus Bowen
– Head and neck = 2 
– Arms = 1
– Legs = 2
– Trunk = 5
Squamous cell carcinoma
– Head and neck = 0 
– Arms = 3
– Legs = 0
– Trunk = 2
Basal cell carcinoma
Actinic keratosis
Morbus Bowen
Squamous cell carcinoma
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Fig. 2. Distribution of DSAP and concomitant cutaneous malignancies in the treatment population (cumulative 
view). Color intensity reflects presentation of lesions in marked area. 
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a b c
a b c
 Fig. 3. Patient No. 3: clinical presentation of DSAP and response to RTx.  a DSAP lesions, distributed on lower 
legs and lower arms (not shown in the picture).  b 15 months after RTx of left lower leg and marking for the ther-
apy of the knee region.  c 17 months after therapy on the lower leg and 2 months after therapy of the knee region 
shows clearing of the lesions. 
 Fig. 4. Patient No. 6: clinical presentation of DSAP and response to RTx.  a Areas marked for RTx of DSAP and 
concomitant Bowen’s carcinoma on the left forearm.  b Grade 3 radiodermatitis after therapy with soft rays (20 
kV, 4 Gy × 10 sessions, total 40 Gy) on the area with the carcinoma and with grenz rays (10 kV, 6 Gy × 8 sessions, 
total 48 Gy) on the area with actinic parakeratosis.  c 2.5 months after therapy of the left forearm shows clearing 
of the lesions. 
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veloped DSAP on ultraviolet-exposed areas and the ma-
jority had pre- or malignant lesions in the same fields sug-
gests defects in the DNA repair machinery as a possible 
trigger of the condition. 
 DSAP usually affects larger areas of the skin, which 
makes it difficult to treat with local therapies. Medica-
tions, used for the treatment of actinic keratosis, such as 
5-fluorouracil, diclofenac gel 3%, imiquimod, retinoid 
and ingenol mebutate, or topical glucocorticoids could be 
suggested, but all show a limited effect  [8] . In a retrospec-
tive study of Tan and Chong  [9] , a good response was 
achieved in only 15 and partial response in 53 of 94 pa-
tients, treated with various methods and for any type of 
porokeratosis. Larger areas of DSAP could be treated with 
PDT, but conventional PDT is a painful treatment option 
and shows conflicting results  [10] , whereas daylight PDT 
is a better tolerated option and has demonstrated a posi-
tive effect in 2 patients  [11] , but further investigations are 
needed.
 Ultrasoft X-rays, used for RTx, are at the short-wave-
length end of the electromagnetic spectrum (1 pm to 1 
nm). RTx is known to cause DNA damage and cell death, 
mainly affecting rapidly dividing cells  [12] . It has recent-
ly been reported to stimulate the expression of cancer-
testis antigens and MHC-I molecules of tumor cells  [13] , 
as well as to cause local activation of complement  [14] and 
increasing immune reaction in such a manner. Grenz 
rays have been reported to be a good treatment option for 
a number of inflammatory skin conditions  [15] . Given 
the superficial location of pathology, low-energy radia-
tion, such as grenz and soft rays (20 kV), that is absorbed 
within the first 2 mm of the skin  [16] , is suitable for the 
treatment of DSAP. The large field of irradiation as well 
as the possibility to adjust RTx to simultaneously treat 
malignancies, arising within DSAP, makes RTx an ap-
pealing therapy option. The recurrence rate after soft ray 
RTx was reported to be 13% in squamous cell carcinoma 
 [17] and 15.8% in basal cell carcinoma  [18] . Results from 
these studies along with an obvious clinical improvement 
noted in all of our patients with only 1 suspected relapse 
give a promising outlook for RTx as treatment option 
for DSAP. Nevertheless, larger clinical studies should be 
performed to provide more data regarding efficacy and 
safety.
 Although an acute reaction to RTx is inevitable, it is 
usually mild in severity, transient and occurs only at the 
application site. It can be easily managed with black-tea 
dressings and hyaluronic acid cream, which makes RTx 
with grenz and soft rays a well-tolerable therapy.
 Key Message 
 Radiotherapy with grenz rays could be a good treatment option 
for patients with disseminated superficial actinic porokeratosis.
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